Smith & Nephew SNATS Net Income 2006-2018 | SNN

Smith & Nephew SNATS annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Smith & Nephew SNATS net income for the quarter ending December 31, 2018 was $0.000B, a NAN% increase year-over-year.
  • Smith & Nephew SNATS net income for the twelve months ending December 31, 2018 was $0M, a 100% decline year-over-year.
  • Smith & Nephew SNATS annual net income for 2018 was $0.663B, a 13.56% decline from 2017.
  • Smith & Nephew SNATS annual net income for 2017 was $0.767B, a 2.17% decline from 2016.
  • Smith & Nephew SNATS annual net income for 2016 was $0.784B, a 91.22% increase from 2015.
Smith & Nephew SNATS Annual Net Income
(Millions of US $)
2018 $663
2017 $767
2016 $784
2015 $410
2014 $501
2013 $556
2012 $729
2011 $582
2010 $615
2009 $472
2008 $377
2007 $316
2006 $745
2005 $341
Smith & Nephew SNATS Quarterly Net Income
(Millions of US $)
Q4 2018 $0
Q2 2018 $0
Q4 2017 $0
Q2 2017 $0
Q4 2016 $0
Q4 2015 $0
Q2 2015 $0
Q4 2014 $160
Q3 2014 $102
Q2 2014 $89
Q1 2014 $150
Q4 2013 $162
Q3 2013 $122
Q2 2013 $129
Q1 2013 $143
Q4 2012 $142
Q3 2012 $134
Q2 2012 $292
Q1 2012 $161
Q4 2011 $140
Q3 2011 $133
Q2 2011 $153
Q1 2011 $156
Q4 2010 $182
Q3 2010 $137
Q2 2010 $137
Q1 2010 $159
Q4 2009 $128
Q3 2009 $128
Q2 2009 $118
Q1 2009 $98
Q4 2008 $115
Q3 2008 $74
Q2 2008 $103
Q1 2008 $83
Q4 2007 $101
Q3 2007 $13
Q2 2007 $111
Q1 2007 $91
Q4 2006 $140
Q3 2006 $93
Q2 2006 $100
Q1 2006 $419
Q4 2005 $88
Q3 2005 $62
Q2 2005 $98
Q1 2005 $93
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.786B $4.904B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $133.667B 26.06
Medtronic (MDT) Ireland $114.132B 16.69
Stryker (SYK) United States $69.756B 24.90
Boston Scientific (BSX) United States $49.905B 24.25
Baxter (BAX) United States $39.019B 25.03
Zimmer Biomet Holdings (ZBH) United States $25.114B 16.07
Canopy Growth (CGC) Canada $16.315B 0.00
ResMed (RMD) United States $14.544B 27.58
Aurora Cannabis (ACB) Canada $9.179B 64.71
Bio-Rad Laboratories (BIO) United States $8.795B 50.45
Perrigo (PRGO) Ireland $6.734B 10.92
Hill-Rom Holdings (HRC) United States $6.397B 19.79
GW Pharmaceuticals (GWPH) United Kingdom $4.994B 0.00
Insulet (PODD) United States $4.964B 1664.20
ICU Medical (ICUI) United States $4.636B 28.71
Haemonetics (HAE) United States $4.354B 38.62
Hutchison China MediTech (HCM) China $3.962B 0.00
Agios Pharmaceuticals (AGIO) United States $3.443B 0.00
Neogen (NEOG) United States $3.004B 48.85
NuVasive (NUVA) United States $2.967B 25.77
Quidel (QDEL) United States $2.487B 22.25
National Vision Holdings (EYE) United States $2.276B 44.77
Aphria (APHA) $1.957B 0.00
HEXO (HEXO) $1.474B 0.00
Phibro Animal Health (PAHC) United States $1.338B 19.24
VAREX IMAGING (VREX) United States $1.234B 24.16
Cardiovascular Systems (CSII) United States $1.212B 870.25
AtriCure (ATRC) United States $1.076B 0.00
Lantheus Holdings (LNTH) United States $0.957B 25.86
Omeros (OMER) United States $0.929B 0.00
PetIQ (PETQ) United States $0.865B 24.76
Cerus (CERS) United States $0.831B 0.00
MacroGenics (MGNX) United States $0.820B 0.00
NanoString Technologies (NSTG) United States $0.781B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.725B 24.66
TG Therapeutics (TGTX) United States $0.717B 0.00
Evolus (EOLS) United States $0.708B 0.00
OraSure Technologies (OSUR) United States $0.589B 25.68
Surmodics (SRDX) United States $0.584B 84.94
LeMaitre Vascular (LMAT) United States $0.555B 26.37
Meridian Bioscience (VIVO) United States $0.538B 16.02
Quanterix (QTRX) United States $0.515B 0.00
Insys Therapeutics (INSY) United States $0.332B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.329B 0.00
Utah Medical Products (UTMD) United States $0.326B 21.19
BioLife Solutions (BLFS) United States $0.302B 124.61
Vapotherm (VAPO) United States $0.287B 0.00
Rockwell Medical (RMTI) United States $0.270B 0.00
Cytosorbents (CTSO) United States $0.228B 0.00
Owens & Minor (OMI) United States $0.213B 2.91
Zynex (ZYXI) United States $0.172B 18.38
Bovie Medical (APYX) United States $0.140B 0.00
Chimerix (CMRX) United States $0.138B 0.00
Fonar (FONR) United States $0.128B 6.85
Chembio Diagnostics (CEMI) United States $0.122B 0.00
Surface Oncology (SURF) United States $0.114B 0.00
United-Guardian (UG) United States $0.089B 20.32
Female Health (VERU) United States $0.088B 0.00
InfuSystems Holdings (INFU) United States $0.085B 0.00
Neurotrope (NTRP) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.069B 0.00
Trinity Biotech (TRIB) Ireland $0.067B 19.86
GUARDION HEALTH (GHSI) United States $0.054B 0.00
ImmuCell (ICCC) United States $0.045B 0.00
Senestech (SNES) United States $0.036B 0.00
Valeritas Holdings (VLRX) United States $0.031B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.024B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
Akers Biosciences Inc (AKER) United States $0.011B 0.00
NeuroMetrix (NURO) United States $0.007B 13.00